Tiragolumab clinical trials
Also written MTIG7192A and RO7092284.
ClinicalTrials.gov finds 67 studies for Tiragolumab. How that becomes 65 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives Tiragolumab. Its counts are asked again every night. How drug pages count
- 67Found by its intervention search · See all 67 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 63 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNCT07350070 · Not given; the arms give tislelizumab, lenvatinib and carvedilolReport a problem
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 67Give Tiragolumab to participants
- −2Give it beside what is tested
- 65Test it: the count on this site
Get an email when these change. Save the Tiragolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
65 studies that test it; most in 2023 (16)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 10 |
| 2021 | 9 |
| 2022 | 7 |
| 2023 | 16 |
| 2024 | 4 |
| 2025 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 35 · Other 30
Hoffmann-La Roche (31) · M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (4) · Genentech, Inc. (4) · Alliance Foundation Trials, LLC. (2) · Omico (1) · Georgetown University (1) · Alain Algazi (1)
Often tested with
Tested in the same studies.
Atezolizumab (13) · Bevacizumab (6) · Tobemstomig (5) · Cobimetinib (4) · Inavolisib (4) · Ipatasertib (4) · Tocilizumab (3) · Gemcitabine (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test Tiragolumab.
- Nov 2026Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCPhase 2 · Georgetown University
- Dec 2026NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingPhase 2 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Dec 2026A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerPhase 2 · Hoffmann-La Roche
- Dec 2026Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaPhase 2 · M.D. Anderson Cancer Center
- Feb 2027Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCPhase 2 · Alliance Foundation Trials, LLC.
- Jul 2027A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryPhase 2 · M.D. Anderson Cancer Center
- Jul 2027A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Phase 1/2 · Hoffmann-La Roche
- Jul 2027Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckPhase 2 · Alain Algazi
Studies
Open first, then newest update. How each study uses Tiragolumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 65
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223With atezolizumab in colorectal cancer arms of a platform studyWritten as TiragolumabHow we knowReport a problem
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as TiragolumabHow we knowReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With atezolizumab in one endometrial cancer cohortWritten as TiragolumabHow we knowReport a problem
- Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsRecruitingPhase 2University Medical Center GroningenNCT05483400With atezolizumab in a basket of solid tumoursWritten as Tiragolumab and atezolizumabHow we knowReport a problem
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingPhase 2The Netherlands Cancer InstituteNCT06342037With atezolizumab, ipilimumab or both in triple-negative breast cancerWritten as TiragolumabHow we knowReport a problem
- Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC PatientsRecruitingPhase 1/2National Taiwan University HospitalNCT05743504With atezolizumab and chemoradiotherapy before oesophageal surgeryWritten as TiragolumabHow we knowReport a problem
- Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)RecruitingPhase 1Centre Georges Francois LeclercNCT05259319With atezolizumab and stereotactic radiotherapy in oligometastatic cancersWritten as TiragolumabHow we knowReport a problem
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05286801Alone and with atezolizumab in SMARCB1- or SMARCA4-deficient tumoursWritten as TiragolumabHow we knowReport a problem
- Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05681039With atezolizumab around surgery in oral cavity cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT04294810Added to atezolizumab against placebo in PD-L1-high lung cancerWritten as TiragolumabHow we knowReport a problem
- Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05715281With atezolizumab in advanced rare cancersWritten as TiragolumabHow we knowReport a problem
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaCompletedPhase 2Hoffmann-La RocheNCT05805501Added to new tobemstomig and axitinib in kidney cancerWritten as TiragolumabHow we knowReport a problem
- Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsActive, not recruitingPhase 2OmicoNCT06003621With atezolizumab in advanced solid tumours, seeking a signalWritten as TiragolumabHow we knowReport a problem
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05645692Added to new tobemstomig in urothelial cancerWritten as TiragolumabHow we knowReport a problem
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT06760481With atezolizumab and RadScopal radiotherapy in advanced solid tumoursWritten as TiragolumabHow we knowReport a problem
- Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)CompletedPhase 2Grupo Espanol Multidisciplinario del Cancer DigestivoNCT05661188With atezolizumab and chemoradiotherapy in anal cancerHow we knowReport a problem
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06754501With atezolizumab in cancer of unknown primaryWritten as TiragolumabHow we knowReport a problem
- Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05394337With atezolizumab before bladder removal in urothelial cancerWritten as TiragolumabHow we knowReport a problem
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingPhase 2Alliance Foundation Trials, LLC.NCT05798663Added to atezolizumab around chemoradiotherapy in stage III lung cancerWritten as TiragolumabHow we knowReport a problem
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT04665856Added to atezolizumab and chemotherapy in small cell lung cancer, ChinaWritten as TiragolumabHow we knowReport a problem
See all 65 studies that test Tiragolumab →
Tested on its own · 1 — no other medicine in its arm
Tested with established drugs · 36 — they are given beside it
- Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid TumorsRecruitingPhase 2University Medical Center GroningenNCT05483400With atezolizumab in a basket of solid tumoursWritten as Tiragolumab and atezolizumabHow we knowReport a problem
- NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingPhase 2The Netherlands Cancer InstituteNCT06342037With atezolizumab, ipilimumab or both in triple-negative breast cancerWritten as TiragolumabHow we knowReport a problem
- Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)RecruitingPhase 1Centre Georges Francois LeclercNCT05259319With atezolizumab and stereotactic radiotherapy in oligometastatic cancersWritten as TiragolumabHow we knowReport a problem
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT05286801Alone and with atezolizumab in SMARCB1- or SMARCA4-deficient tumoursWritten as TiragolumabHow we knowReport a problem
- Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05681039With atezolizumab around surgery in oral cavity cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT04294810Added to atezolizumab against placebo in PD-L1-high lung cancerWritten as TiragolumabHow we knowReport a problem
- Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05715281With atezolizumab in advanced rare cancersWritten as TiragolumabHow we knowReport a problem
- Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsActive, not recruitingPhase 2OmicoNCT06003621With atezolizumab in advanced solid tumours, seeking a signalWritten as TiragolumabHow we knowReport a problem
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT06760481With atezolizumab and RadScopal radiotherapy in advanced solid tumoursWritten as TiragolumabHow we knowReport a problem
- A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06754501With atezolizumab in cancer of unknown primaryWritten as TiragolumabHow we knowReport a problem
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT04665856Added to atezolizumab and chemotherapy in small cell lung cancer, ChinaWritten as TiragolumabHow we knowReport a problem
- Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingPhase 2Georgetown UniversityNCT04958811With atezolizumab and bevacizumab in previously treated lung cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedPhase 3Hoffmann-La RocheNCT04540211With atezolizumab added to chemotherapy in oesophageal cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05009069Added to atezolizumab after chemoradiotherapy in rectal cancerWritten as TiragolumabHow we knowReport a problem
- NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT05825625With atezolizumab and chemotherapy around lung cancer surgeryWritten as TiragolumabHow we knowReport a problem
- A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsCompletedPhase 2Hoffmann-La RocheNCT05661578As a fixed-dose combination with atezolizumabWritten as Tiragolumab and Atezolizumab IV FDCHow we knowReport a problem
- A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyTerminatedPhase 3Hoffmann-La RocheNCT06267001Added to atezolizumab after resected lung cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT04513925With atezolizumab against durvalumab after chemoradiotherapy in lung cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerCompletedPhase 2/3Hoffmann-La RocheNCT04619797With atezolizumab and chemotherapy against pembrolizumab in lung cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Hoffmann-La RocheNCT04665843Added to atezolizumab in PD-L1-positive head and neck cancerWritten as TiragolumabHow we knowReport a problem
Showing 20 of 36. See all 36 →
Tested in a combination · 28 — another drug in the study is under test too
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223With atezolizumab in colorectal cancer arms of a platform studyWritten as TiragolumabHow we knowReport a problem
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as TiragolumabHow we knowReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With atezolizumab in one endometrial cancer cohortWritten as TiragolumabHow we knowReport a problem
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaCompletedPhase 2Hoffmann-La RocheNCT05805501Added to new tobemstomig and axitinib in kidney cancerWritten as TiragolumabHow we knowReport a problem
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05645692Added to new tobemstomig in urothelial cancerWritten as TiragolumabHow we knowReport a problem
- Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)CompletedPhase 2Grupo Espanol Multidisciplinario del Cancer DigestivoNCT05661188With atezolizumab and chemoradiotherapy in anal cancerHow we knowReport a problem
- Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05394337With atezolizumab before bladder removal in urothelial cancerWritten as TiragolumabHow we knowReport a problem
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingPhase 2Alliance Foundation Trials, LLC.NCT05798663Added to atezolizumab around chemoradiotherapy in stage III lung cancerWritten as TiragolumabHow we knowReport a problem
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedPhase 1/2Hoffmann-La RocheNCT05908786Added to atezolizumab and bevacizumab before liver cancer surgeryWritten as TiragolumabHow we knowReport a problem
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedPhase 3Hoffmann-La RocheNCT04543617Added to atezolizumab after chemoradiotherapy in oesophageal cancerWritten as TiragolumabHow we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingPhase 1/2Hoffmann-La RocheNCT04524871Added to atezolizumab and bevacizumab in one liver cancer armWritten as TiragolumabHow we knowReport a problem
- Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckActive, not recruitingPhase 2Alain AlgaziNCT03708224Added to atezolizumab before head and neck cancer surgeryWritten as TiragolumabHow we knowReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369With atezolizumab in oesophageal cancer arms of a platform studyWritten as TiragolumabHow we knowReport a problem
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedPhase 1/2Hoffmann-La RocheNCT03869190Added to atezolizumab in bladder cancer arms of a platform studyWritten as TiragolumabHow we knowReport a problem
- Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03784326Added to atezolizumab and FOLFOX before oesophageal surgeryWritten as TiragolumabHow we knowReport a problem
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698With atezolizumab in lung cancer arms of a platform studyWritten as TiragolumabHow we knowReport a problem
- Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedPhase 2Mayo ClinicNCT03554083With atezolizumab before surgery in stage III melanomaWritten as TiragolumabHow we knowReport a problem
- A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical CancerCompletedPhase 2Hoffmann-La RocheNCT04300647Added to atezolizumab in PD-L1-positive cervical cancerWritten as TiragolumabHow we knowReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Added to atezolizumab and chemotherapy in one pancreatic cancer armWritten as TiragolumabHow we knowReport a problem
- Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal CancerActive, not recruitingPhase 2University of Colorado, DenverNCT06784947With atezolizumab and bevacizumab in MSS colorectal cancerWritten as TiragolumabHow we knowReport a problem
Showing 20 of 28. See all 28 →
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests
- A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT05459129In every armIn every arm; carboplatin and paclitaxel are added in oneWritten as TiragolumabHow we knowReport a problem
What changed recently
From the registry's own updates since Oct 20, 2026.
Codes
What other systems call Tiragolumab · ClinicalTrials.gg INT002091
- MeSH (NLM) C000730814TiragolumabOne source ClinicalTrials.gov
- UNII (FDA) 6XG22YQM2ZTIRAGOLUMABOne source FDA
- NCI Thesaurus C131291TiragolumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730814 | Tiragolumab | One source ClinicalTrials.gov |
| UNII (FDA) | 6XG22YQM2Z | TIRAGOLUMAB | One source FDA |
| NCI Thesaurus | C131291 | Tiragolumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.